 I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to US20 million of its ordinary shares in the form of American depositary shares. 